Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients - Ghiringhelli, F; Menard, C; Puig, P E (Cancer Immunol Immunother, 2007)
et al.